News & Analysis on Clinical Trial Services & Contract Research And Development
News from SciFluor, NinePoint and Abbott India – People on the move
By Natalie Morrison
- Last updated on
Abbott India has drafted Vivek Mohan and Rehan Khan into senior level positions.
Mohan is currently the managing director of Abbott India. He will now become senior director, of global integrated health of the established pharmaceuticals division, and will take charge of operations throughout the all of the group’s divisions.
Currently the general manager and country head of Abbott Nutrition, India, Khan will now be the businesses managing director. Senior VP of the established pharmaceuticals division, Michael Warmuth the establishment of the roles “with a global scope, based out of India” reflects the firm’s recognition of the importance of the region.
Fluorine-based drug developer SciFluor Life Sciences has expanded its management team with the appointment of Mark Duggan, Scott Edwards, and Naina Bhasin.
Duggan will become VP of scientific operations. Prior to SciFluor, he was VP of chemistry and preclinical development at Link Medicine. He also spent 18 years working for Merck Research Laboratories.
Bristol-Myers Squibb veteran Edwards will become VP and general manager of imaging. Before taking up his new role, he was most recently VP of R&D (research and development) at Lantheus Medical Imaging.
And Bhasin takes on the role of VP of business development, after leaving The Hamner Institutes, where she served in the same role.
SciFluor CEO Arthur Hiller said: “The combination of this talented group of executives and our novel fluorine technologies provides SciFluor with a unique opportunity to establish strategic industry partnerships that have the potential to advance drug discovery and development, and to ultimately improve patient care.”
The Myelin Repair Foundation (MRF) has placed Biogen Idec VP Alfred Sandrock onto its clinical advisory board.
Sandrock will help lead the firm’s myelin repair programs for the treatment of MS (multiple sclerosis).
He is currently VP of development sciences and CMO at Biogen Odec.
“The multiple sclerosis community holds the deepest respect for Dr. Sandrock's invaluable contributions to developing MS therapeutics that already treat millions of patients,” said Scott Johnson, president of the MRF.
“We are pleased that Dr. Sandrock will join our efforts to advance myelin repair therapeutics to reach MS patients soon.”
NinePoint Medical has appointed Patrick MacCarthy as VP of marketing.
The in vivo pathology tech developer said hiring MacCarthy is part of plans to strengthen the management team in time for the launch of its new imaging platform.
A spokesperson said: “Patrick’s broad medical device expertise will be invaluable as NinePoint Medical continues to strengthen its management team and prepare for the commercial launch of the Nvision VLE imaging system next year.”
He joins the firm from Olympus America, where he was VP of marketing for the medical device and equipment section of the biz.
Bill Williams is set to take on the full time role of CFO for pharma wholesaler H.D. Smith, after serving as interim.
He first came to the firm from Tatum, a firm specialising in interim executive staffing.
Throughout his career he has filled various executive positions including senior VP, CFO, chief operating officer and management consultant in chemicals, distribution, automotive, consumer products and technology companies.
"Bill has brought perspective to this pharmaceutical wholesale enterprise that elevates our customer excellence and accelerates our growth plan," said Dale Smith, chairman and CEO.
Dave Lemus has become chief operating officer at Sigma-Tau Pharmaceuticals.
Before joining the medical commercialisation specialist, Lemus was CFO for MorphoSys, where he launched Germany’s first biotech IPO in 1999.
Trevor Jones, president of the company, said: "We are delighted to appoint Dave to lead our efforts to expand the world-class rare disease business we have established in the US. Dave brings a wealth of relevant pharmaceutical and biotech experience from both the US. and Europe.”